Uslu U, Erdmann M, Schliep S, Dörrie J, Schaft N, Schuler G, Schuler-Thurner B (2017)
Publication Type: Journal article
Publication year: 2017
Book Volume: 37
Pages Range: 3243-3248
Journal Issue: 6
DOI: 10.21873/anticanres.11687
Sarcoidosis, a chronic inflammatory disorder, results from increased immune responses. Its development can be triggered in patients under immunotherapy, as activation of the immune system in these patients is desired. Since 1997, 249 patients with metastasized cutaneous melanoma (stage III and IV, AJCC 2009) have been treated with dendritic cell (DC)-based vaccines at our hospital. Three out of these patients were diagnosed with sarcoidosis after or during long-term DC vaccination therapy (1.20%). Metastatic disease was initially suspected based on the radiographic manifestation of lung masses or bilateral hilar lymphadenopathy. Histological assessment, however, revealed the appropriate diagnosis. Interestingly, all three patients are long-term responders and have remained free of metastatic or progressive disease for over a period of at least 4 years. In summary, sarcoidosis can occur in patients with cancer who have benefited from DC-based therapeutic vaccination and thus, its development, even with substantial delay, may be associated with successful anticancer immunotherapy.
APA:
Uslu, U., Erdmann, M., Schliep, S., Dörrie, J., Schaft, N., Schuler, G., & Schuler-Thurner, B. (2017). Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma. Anticancer Research, 37(6), 3243-3248. https://doi.org/10.21873/anticanres.11687
MLA:
Uslu, Ugur, et al. "Sarcoidosis Under Dendritic Cell Vaccination Immunotherapy in Long-term Responding Patients with Metastatic Melanoma." Anticancer Research 37.6 (2017): 3243-3248.
BibTeX: Download